GlassScriptPhysician profile
Abid B Darr
NPI 1871940783
$4,710.44
in general payments reported to CMS, 2019-2025
17 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what a typical Behavioral Neurology & Neuropsychiatry provider received nationally (typical 2025 total: $153).
See the full distribution for Behavioral Neurology & Neuropsychiatry
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $405 · 2021: $247 · 2022: $567 · 2023: $907 · 2024: $711 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,618.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $928.21 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $859.01 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $844.24 | 2019-2025 | Invega Sustenna |
| Alkermes, INC. | $541.86 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $484.76 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $247.97 | 2023-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $100.04 | 2025 | Cobenfy |
| Luye Pharma (USA) LTD. | $91.53 | 2025 | Erzofri Extended-Release |
| Indivior INC. | $90.32 | 2019-2024 | Perseris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $89.52 | 2022 | |
| Corium, LLC | $84.93 | 2023-2024 | Azstarys, Azstarys |
| Abbvie INC. | $68.68 | 2021-2024 | |
| Lundbeck LLC | $66.86 | 2020-2024 | Rexulti |
| Axsome Therapeutics, INC. | $66.41 | 2025 | Auvelity |
| Bioxcel Therapeutics, INC. | $65.94 | 2023 | Igalmi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $57.78 | 2021-2025 | Fanapt |
| Allergan, INC. | $22.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abid Darr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.